MannKind Corp. (MNKD)

[redfalcon2]

From October 21st:

Fortunately, the lack of confidence isn't particularly worrisome for MannKind. As part of its recently signed deal with Sanofi to market Afrezza, MannKind received $150 million up front, and Sanofi is loaning MannKind up to another $175 million to cover the losses from their partnership until Afrezza is profitable.

MannKind shouldn't need to raise capital in the near future, so the share price in the short term isn't a concern. (And even if it did need to raise capital, billionaire namesake and CEO Alfred Mann can continue to help foot the bill.) If Sanofi and MannKind can prove that doctors are willing to adopt inhaled insulin, investors will come back and MannKind's share price will go up substantially. And that would make everyone dance.